Healthcare Industry News: GSK
News Release - January 8, 2008
NuPathe Names George Moonsammy, Ph.D. as Vice President of DevelopmentPositions NuPathe to Advance NP101 SmartRelief(TM) Transdermal Drug Delivery Technology Toward Commercialization
CONSHOHOCKEN, Pa.--(HSMN NewsFeed)--NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced that George Moonsammy, Ph.D. has been appointed Vice President of Development. Dr. Moonsammy has more than 30 years of domestic and international expertise in clinical studies. Dr. Moonsammy most recently served as Senior Vice President, Clinical, Regulatory, and Medical Affairs at Somerset Pharmaceuticals, Tampa, Florida. In that role, he spearheaded the NDA filing and approval of EMSAM, the first transdermal product for the treatment of patients with depression.
“George’s record of numerous successful clinical filings and particularly his most recent experience regarding the filing, approval and launch of the first transdermal patch for depression will be extremely valuable as NuPathe continues to advance toward late stage development and product commercialization opportunities,” said Terri Sebree, president of NuPathe Inc.
Prior to joining Somerset Pharmaceuticals, Dr. Moonsammy spent twenty-nine years at GlaxoSmithKline (NYSE:GSK ) in Philadelphia, Pennsylvania. He started as a biological research scientist in research and development and worked his way up to Associate Director – Clinical Research and Development and US Medical Affairs. In that capacity, he directed clinical research of investigational pharmaceutical and vaccine products that resulted in the filings of 12 New Drug Applications (NDA’s)/supplemental NDA’s/Biological Licensing Applications (BLA’s) in anti-infective, anti-virals and vaccine products.
Dr. Moonsammy has a B.S degree in chemistry/biology from St. Louis University, an M.A. in Neurobiology from the Washington University School of Medicine and a Ph.D. in Pharmacology from the Union Institute and University in Cincinnati, Ohio.
Migraine is an episodic headache disorder associated with various combinations of neurologic, gastrointestinal, and autonomic symptoms that affects approximately 28 million Americans, mostly women. Gastrointestinal disturbances, including nausea and vomiting, are common with nausea occurring in over 90% and vomiting in nearly 70% of the migraine population. Among those experiencing nausea, nearly one-third experience nausea with every migraine attack and, for 3 in 10, the migraine-associated nausea interferes with their ability to take oral medications.1 This underscores the clinical need for novel treatments that address the gastrointestinal issues associated with migraine and formed the rationale for developing NP101.
NuPathe Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. NuPathe’s mission is to identify and address the needs of patients that are insufficiently met by current treatments.
NuPathe’s product portfolio includes NP101, a transdermal patch for the treatment of acute migraine, and NP201, an injectable implant for the long-term management of Parkinson’s disease symptoms.
NP101 is a novel treatment for acute migraine based upon NuPathe’s proprietary SmartRelief™ transdermal technology, an iontophoretic drug delivery system which uses low level electrical energy to transport drug through the skin in a controlled manner. Pending regulatory review and approval, NP101 will be the first patch for treatment of migraine. By avoiding absorption through the gastrointestinal tract, NP101 may be an attractive option for migraine patients - convenient, consistent, and controlled delivery of medication regardless of nausea, vomiting, or other gastric symptoms associated with migraine.
For additional information, visit www.nupathe.com.
(1)Stephen D Silberstein M.D (1995) Migraine Symptoms: Results of a Survey of Self-Reported Migraineurs Headache: The Journal of Head and Face Pain 35 (7), 387–396.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.